Platinum polymeric anticancer compounds

The polymeric nature may inhibit premature drug deactivation. Thus, cisplatin (structure 19.20), the most widely used anticancer drug, is converted into numerous inactive, but more toxic, platinum-containing compounds before it arrives at the targeted cancer cells. Placement of the active platinum-containing moiety into a polymer (structure 19.21) decreases this tendency to hydrolyze into these unwanted cisplatin compounds because of the greater hydrophobic character of the polymeric drug. 

---